Ryan D. Maynard - 08 Feb 2024 Form 4 Insider Report for Cara Therapeutics, Inc. (TVRD)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: TVRD
Reported as of: 08 Feb 2024
Net transaction value: -$2,909
SEC form: 4
Accepted by SEC: 12 Feb 2024, 17:15:08 UTC
Prior SEC filing: 05 Feb 2024
Next SEC filing: 05 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Darren DeStefano, Attorney-in-Fact

Key filing fact

Ryan D. Maynard filed Form 4 for Cara Therapeutics, Inc. (TVRD) on 12 Feb 2024.

Key facts

This page summarizes Ryan D. Maynard's Form 4 filing for Cara Therapeutics, Inc. (TVRD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Feb 2024, 17:15.

Change

Previous filing in this sequence was filed on 05 Feb 2024.
Current net transaction value: -$2,909.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CARA transaction

Common Stock

Sale

Transaction value: $2,909
Shares: -5,488
Change %: -41%
Price: $0.5300
Shares after: 8,012
Date: 08 Feb 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 14, 2023 accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.